The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review)
Open accessAbstract
Inflammation is a defense strategy against invading agents and harmful molecules that is activated immediately following a stimulus, and involves the release of cytokines and chemokines, which activate the innate immune response. These mediators act together to increase blood flow and vascular permeability, facilitating recruitment of effector cells to the site of injury. Following resolution of the injury and removal of the stimulus, inflammation is disabled, but if the stimulus persists, inflammation becomes chronic and is strongly associated with cancer. This is likely to be due to the fact that the inflammation leads to a wound that does not heal, requiring a constant renewal of cells, which increases the risk of neoplastic transformation. Debris from phagocytosis, including the reactive species of oxygen and nitrogen that cause damage to DNA already damaged by the leukotrienes and prostaglandins, has an impact on inflammation and various carcinogenic routes. There is an association between chronic inflammation, persistent infection and cancer, where oncogenic action is mediated by autocrine and paracrine signals, causing changes in somatic cells under the influence of the microbial genome or of epigenetic factors. Among the infectious agents associated with cancer, certain genotypes of human papillomavirus (HPV) stand out. HPV is responsible for virtually all cases of cervical cancer and a lower proportion of cancers of the vagina, vulva, anus, penis and a number of extragenital cancers. In the present review, recent advances in the mechanisms involved in the inflammatory response are presented with their participation in the process of carcinogenesis, emphasizing the role of chronic inflammation in the development of HPV-induced cervical cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 1×
“Oncoproteins that are associated with cancer, including Ras, Myc and RET, can also cause inflammation via the activation of signaling mechanisms involved in the production of proinflammatory cytokines and chemokines (64).”
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618 · cited 1×
“Once activated, proinflammatory cytokines, including tumor necrosis factor (TNF), interleukin (IL)‑1 β and IL‑6 are produced, but once the stimulus is removed, inflammation becomes naturally regulated and returns to its normal state (39).”
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Points of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738 · cited 2×
“TAMs can kill tumor cells following activation by IL‑2, IFN‑ γ and IL‑12, but they also produce IL‑10, which inhibits the CTL‑mediated antitumor response and therefore promotes tumor progression (5,48,49).”
Resolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552 · cited 1×
“…precedes a highly‑regulated process, known as the resolution of inflammation, which is controlled by various anti‑inflammatory mediators, particularly IL‑10, transforming growth factor (TGF)‑ β and glucocorticoids, involving the recruitment of monocytes for the cleaning of cell debris (40).”
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Interferon-inducible antiviral effectors
Sadler, A. J., & Williams, B. R. G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2314 · Cited by 2,160
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940 · cited 1×
“…antitumor effects by inducing tumor cell apoptosis, IL‑10 exerts antitumor effects through its anti‑inflammatory action and IL‑12 exerts antitumor effects by activating CTLs and natural killer (NK) cells and through the expression of cytotoxic mediators, which can lead to tumor suppression (50).”
Hussain, S. P., Hofseth, L. J., & Harris, C. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1046 · Cited by 1,690 · cited 1×
“TNF‑ α Inflammatory and TNF‑ α stimulates the growth and survival of tumor cells, exhibits antiapoptotic action, facilitates tumor cells tumor progression, promotes angiogenesis and decreases immune surveillance by suppressing the cytotoxic activity of T lymphocytes and activated macrophages (19).”
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Papillomaviruses in the causation of human cancers - a brief historical account
zur Hausen, H. (2009) · Virology · doi:10.1016/j.virol.2008.11.046 · Cited by 1,532
Chapter 1: HPV in the etiology of human cancer
Muñoz, N., Castellsagué, X., de González, A. B., & Gissmann, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.115 · Cited by 1,355 · cited 5×
“Prior to the discovery of the HPV, infection with C. trachomatis and HSV‑2 were considered to be major risk factors for the development of ICC.”
InfluentialKoch, M. A., Tucker-Heard, G., Perdue, N. R., Killebrew, J. R., Urdahl, K. B., & Campbell, D. J. (2009) · Nature Immunology · doi:10.1038/ni.1731 · Cited by 1,258
Viviani, B., Bartesaghi, S., Gardoni, F., Vezzani, A., Behrens, M. M., Bartfai, T., Binaglia, M., Corsini, E., Di Luca, M., Galli, C. L., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-25-08692.2003 · Cited by 893
Ruddy, M. J., Wong, G. C., Liu, X. K., Yamamoto, H., Kasayama, S., Kirkwood, K. L., & Gaffen, S. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308809200 · Cited by 364
Graham, B. S. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00972.x · Cited by 239
Cited by
Brusselaers, N., Shrestha, S., van de Wijgert, J., & Verstraelen, H. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.12.011 · Cited by 317
Immunomodulatory activity of argentatins A and B isolated from guayule
Silva-Nolasco, A. M., de la Cruz-Morcillo, M. A., García-Martínez, M. M., Zalacain, A., Gálvez, B. G., & Carmona, M. (2024) · PLOS ONE · doi:10.1371/journal.pone.0304713 · Cited by 7
Ali, M., Sinha, R., kumar, A., Karim, S., Irfan, M., Kumar, S., Sinha, S., Kumar, A., Ghosh, A., & Singh, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-68344-4 · Cited by 7
Metadata
- Authors
- FERNANDES, J. V., DE MEDEIROS FERNANDES, T. A. A., DE AZEVEDO, J. C. V., COBUCCI, R. N. O., DE CARVALHO, M. G. F., ANDRADE, V. S., & DE ARAÚJO, J. M. G.
- Venue
- Oncology Letters
- Publisher
- Spandidos Publications
- Published
- 2015-01-16
- Volume
- 9
- Issue
- 3
- Pages
- 1015-1026
- ISSN
- 1792-1074 (ISSN-L)
- 1792-1082
- OpenAlex
- W2064157766
- Cited by
- 196
- References
- 19
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.